



ATTD-Asia (Advanced Technologies and Treatments in Diabetes) 2025

December 9-11, 2025; Singapore; Day #1 Highlights – Draft

Welcome to our resource hub for ATTD-Asia 2025! This is a one-stop-shop for all your ATTD-Asia 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Important Conference Information. ATTD-Asia 2025 is being held at the Suntec Singapore Convention Centre. No virtual attendance option is available.

Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Diabetes Technology Highlights](#)

[Diabetes Therapy Highlights](#)

[Diabetes Big Picture Highlights](#)

[Previous ATTD-Asia Coverage on CCKB](#)

Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Day-by-Day Conference Preview](#)
4. [Conference Program](#)

Day-of Conference Reports

1. [ATTD-Asia 2025 Day #1 Highlights](#)
2. [ATTD-Asia 2025 Day #2 Highlights](#)
3. [ATTD-Asia 2025 Day #3 Highlights](#)

Diabetes Technology Highlights

1. [The case for continuous ketone monitoring](#): Profs. Thomas Danne and David O’Neal debate the diabetes ecosystem’s preparedness for this technology
2. [Medtronic School: How predictive automation, optimal settings](#), and flexible strategies drive glycemic outcomes
3. [Medtronic School: AID across all ages: MiniMed 780G for children](#), adolescents, and the elderly
4. [Medtronic School: AID for pregnancy and T2D](#); expanding uses and population-wide health
5. [Abbott School: Dr. Satish Garg on the dual opportunity with CGM and GLP-1 RAs](#) to optimize T1D and T2D management
6. [Abbott School: Tips for translating glycemic data](#) into actionable tasks
7. [Abbott School: Panelists share visions of a future endocrinology clinic](#) including AI, telehealth, precision medicine, and pharmacotherapy
8. [Key opportunities to reshape the state of AID](#) in Southeast Asia

9. [Real-world AID use in pregnancy demonstrates strong glycemic outcomes](#) during the third trimester and when using pregnancy-specific algorithms
10. [Dual glucose-ketone monitoring](#) for earlier DKA detection and safer insulin therapy
11. [Dexcom School](#): CGM as a champion in the battle against elevated glucose levels
12. [Real-world use of MiniMed 780G in Japan and APAC](#): Insights on glycemic outcomes and user behaviors from Prof. O’Neal and Dr. Noriko Kodani
13. [Glycemic rhythms and heart health](#): Prof. Ramzi Ajjan on using CGM to meaningfully reshape cardiovascular risk assessment
14. [Benefits and practical challenges to the implementation of inpatient CGM](#) from Prof. Spiros Fourlanos
15. [AI, wearables, and gut health for prediabetes](#) prevention from Prof. Elaine Chow
16. [Preliminary data presented by Prof. Elizabeth Davis shows early AID onboarding](#) improves glycemic outcomes in Australian pediatric T1D
17. [MiniMed 780G found to be cost effective for Japanese adults with T1D](#) compared to MDI with CGM
18. [Full 26-week RADIANT trial results](#) show sustained glycemic improvements with Omnipod 5 and FreeStyle Libre 2
19. [Real-world analysis identifies five optimal Omnipod 5 settings](#) associated with improved glycemic outcomes
20. [MiniMed 780G delivers additional long-term health and economic benefits](#) in Hong Kong and Australian adults with T1D
21. [Understanding bolus patterns](#) as a key determinant of Omnipod 5 outcomes
22. [Prof. Benjamin Wheeler on AID](#) for those that need it the most
23. [Early insights into ketone patterns in T1D](#) using continuous monitoring
24. [The state of diabetes technology in Japan](#): CGM growth and AID challenges
25. [Dr. Tom Wilkinson presents feasibility results of the second-generation Tandem Freedom FCL algorithm](#) (n=10) in a three-day hotel setting

Diabetes Therapy Highlights

1. [Dr. Jothydev Kesavadev on MASLD/MASH](#) pathophysiology, screening, and management
2. [Beyond AID and CGM](#): Dr. Viral Shah reviews the evidence for GLP-1 RAs in T1D
3. [Dr. Manoj Chawla reviews disease-modifying therapies](#) for pre-T2D
4. [Toward a functional cure for T1D](#): Prof. Thomas Danne on T1TR, T1D “remission”, and cell replacement therapies

Diabetes Big Picture Highlights

1. [Opening session](#): Prof. Juliana Chan on OGTT and CGM in redefining prediabetes and diabetes
2. [Early gestational diabetes \(eGDM\) emerges as a distinct entity](#), prompting work to establish a global consensus
3. [Dr. Viral Shah introduces novel metric, CGM Dynamic Index](#), for diagnosing early dysglycemia
4. [Teasing out the relationships between T1TR, glycemic variability, and diabetes complications](#) with Prof. Ramzi Ajjan
5. [Pathophysiology and interventions for prediabetes](#) in multiple countries throughout Asian from Dr. Anoop Misra
6. [Dr. Viswanathan Mohan on the potential for charitable organizations](#) to change the course of T1D in low- and middle-income countries
7. [Prof. Catarina Limbert on ISPAD’s Declaration of Lisbon 2024](#): An imperative for action for childhood diabetes

8. [Updates on T1D screening and monitoring](#): Screening in Japan and early-stage clinical service in Australia
9. [Increasing rates of GDM](#) are associated with higher maternal age and obesity

Previous ATTD-Asia Coverage on CCKB

- [ATTD-Asia 2024 Resource Hub](#)